FrancophonIA/ELRC3.0 huggingface dataset:
English: As a result, it stops the growth of tumour cells and eventually kills them.
Estonian: Selle tulemusena pärsib see aine kasvajarakkude kasvu ja lõpuks hävitab need.
English: It is used to treat:
Estonian: Seda kasutatakse järgmistel näidustustel:
English: This summary was last updated in 06-2012.
Estonian: Kokkuvõtte viimane uuendus: november 2012.
English: For other types of cancer, treatment is stopped if the disease gets worse or the patient cannot tolerate the treatment.
Estonian: Teiste vähiliikide korral ravi peatatakse, kui haigus süveneb või patsient ei talu ravi.
English: Treatment is continued for six months after colon surgery.
Estonian: Ravi jätkatakse 6 kuu jooksul pärast käärsooleoperatsiooni.
English: The full EPAR for Capecitabine Medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Capecitabine Medaci kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: 5-FU is an analogue of pyrimidine.
Estonian: 5-FU on pürimidiini analoog.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Capecitabine Medac on 19 November 2012.
Estonian: Euroopa Komisjon andis Capecitabine Medaci müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. novembril 2012.
English: It is available as tablets (150, 300 and 500 mg).
Estonian: Seda turustatakse tablettidena (150, 300 ja 500 mg).
English: It is taken as tablets, while 5-FU normally needs to be injected.
Estonian: Seda manustatakse tablettidena, ent 5FU-d on tavaliselt vaja süstida.
English: Capecitabine Medac tablets should be swallowed with water within 30 minutes after a meal.
Estonian: Capecitabine Medaci tabletid võetakse koos veega 30 minuti jooksul pärast sööki.
English: For more information on generic and hybrid medicines, see the questionand-answer document here.
Estonian: Lisateave geneeriliste ja hübriidravimite kohta on teabedokumendis siin.
English: The company provided data from the published literature on capecitabine.
Estonian: Ettevõte esitas kapetsitabiini kohta avaldatud kirjandusest pärinevad andmed.
English: Capecitabine Medac is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient's height and weight).
Estonian: Capecitabine Medaci võetakse kaks korda ööpäevas annustes 625-1250 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kaalu põhjal).
English: The doctor will calculate the number of 150, 300 and 500 mg tablets the patient needs to take.
Estonian: Arst arvutab 150, 300 ja 500 mg tablettide arvu, mille patsient peab manustama.
English: Pyrimidine is part of the genetic material of cells (DNA and RNA).
Estonian: Pürimidiin on raku geneetilise materjali (DNA ja RNA) osa.
English: This means that it is similar to a ‘reference medicine', but it contains capecitabine at a new strength in addition to existing strengths.
Estonian: See on sarnane võrdlusravimiga, kuid sisaldab kapetsitabiini lisaks senistele ravimitugevustele uues tugevuses.
English: The company carried out a ‘bioequivalence' study to show that 500 mg Capecitabine Medac produces the same levels of capecitabine in the blood as 500 mg Xeloda.
Estonian: Ettevõte korraldas bioekvivalentsuse uuringu, millega tõendas, et 500 mg ravimit Capecitabine Medac tekitab veres sama kapetsitabiinisisalduse kui 500 mg Xelodat.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Capecitabine Medac.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
Estonian: 5-FU asendab organismis pürimidiini ja toimib uue DNA sünteesis osalevatele ensüümidele.
English: For more information about treatment with Capecitabine Medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Capecitabine Medaciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Estonian: Euroopa avaliku hindamisaruande täistekst võrdlusravimi kohta on samuti Euroopa Ravimiameti veebilehel.
English: The CHMP concluded that, in accordance with EU requirements, Capecitabine Medac has been shown to have comparable quality and to be bioequivalent to Xeloda.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Capecitabine Medac võrdväärne kvaliteet ja bioekvivalentsus ravimiga Xeloda.
English: Full details are available in the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: The Committee recommended that Capecitabine Medac be given marketing authorisation.
Estonian: Komitee soovitas anda Capecitabine Medaci müügiloa.
English: While the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Capecitabine Accord is also available as 300 mg tablets.
Estonian: Võrdlusravimit Xelodat turustatakse 150 ja 500 mg tablettidena, võrdlusravimit Capecitabine Accordi ka 300 mg tablettidena.
English: Capecitabine Medac capecitabine
Estonian: Capecitabine Medac kapetsitabiin
English: Capecitabine is a ‘prodrug' that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Estonian: Kapetsitabiin on eelravim, mis muundub organismis 5-fluorouratsiiliks (5-FU), kuid kasvajarakkudes muundub seda rohkem kui tervetes kudedes.
English: Because Capecitabine Medac contains the same active substance as its reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Capecitabine Medac sisaldab sama toimetainet kui võrdlusravim, peetakse selle kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for Xeloda, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Xeloda korral, ületab Capecitabine Medaci kasulikkus sellega kaasnevad riskid.
English: This is a summary of the European public assessment report (EPAR) for Capecitabine Medac.
Estonian: See on ravimi Capecitabine Medac Euroopa avaliku hindamisaruande kokkuvõte.
English: The dose depends on the type of cancer being treated.
Estonian: Annus sõltub ravitava vähi liigist.
English: Other information about Capecitabine Medac
Estonian: Muu teave Capecitabine Medaci kohta
English: Doses need to be adjusted for patients with liver or kidney disease and for patients who develop certain side effects.
Estonian: Maksa- või neeruhaigusega patsientidel ja kõrvalnähtude tekkimisel on vaja annuseid kohandada.
English: Capecitabine Medac is used with or without other anticancer medicines in patients who have had surgery for ‘stage III' or ‘Dukes' stage C' colon cancer;
Estonian: • käärsoole- ehk jämesoolevähk: Capecitabine Medaci kasutatakse koos teiste vähiravimitega või ilma nendeta, et ravida käärsoolevähki patsientidel, kellele on tehtud III staadiumi ehk Dukesi skaala C-staadiumi käärsoolevähi operatsioon;
English: Capecitabine Medac is a medicine that contains the active substance capecitabine.
Estonian: Capecitabine Medac on ravim, mis sisaldab toimeainena kapetsitabiini.
English: Why has Capecitabine Medac been approved?
Estonian: Miks Capecitabine Medac heaks kiideti?
English: Capecitabine Medac is a ‘generic' and a ‘hybrid' medicine.
Estonian: Capecitabine Medac on geneeriline ja hübriidravim.
English: The active substance in Capecitabine Medac, capecitabine, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anti-metabolites'.
Estonian: Capecitabine Medaci toimeaine kapetsitabiin on antimetaboliitide (raku normaalset ainevahetust pärssivate ainete) hulka kuuluv tsütotoksiline aine (ravim, mis hävitab poolduvaid rakke, näiteks vähirakke).
English: Capecitabine Medac should only be prescribed by a doctor who is qualified in the use of anticancer medicines.
Estonian: Capecitabine Medaci tohib määrata üksnes vähiravimite pädevusega arst.
English: It can also be used on its own when treatment with both anthracyclines and taxanes (another type of anticancer medicine) has failed or when repeat treatment with anthracyclines is not suitable for the patient.
Estonian: Capecitabine Medaci tohib kasutada ka ainsa ravimina, kui ravi antratsükliinide ja taksaanidega (teist liiki vähiravimid) ei ole andnud tulemust või kui kordusravi antratsükliinidega patsiendile ei sobi.
English: What is Capecitabine Medac?
Estonian: Mis on Capecitabine Medac?
English: How does Capecitabine Medac work?
Estonian: Kuidas Capecitabine Medac toimib?
English: Capecitabine Medac is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin;
Estonian: • kaugelearenenud maovähk: Capecitabine Medaci kasutatakse koos teiste vähiravimitega, sealhulgas plaatinat sisaldava vähiravimiga (näiteks tsisplatiiniga);
English: Capecitabine Medac is an anticancer medicine.
Estonian: Capecitabine Medac on retseptiravim.
English: What are the benefits and risks of Capecitabine Medac?
Estonian: Milles seisneb Capecitabine Medaci kasulikkus ja mis riskid ravimiga kaasnevad?
English: • metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Estonian: • metastaatiline kolorektaalvähk (jämesoolevähk, mis on levinud organismis ka mujale): Capecitabine Medaci kasutatakse koos teiste vähiravimitega või ilma nendeta;
English: • locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Estonian: • paikne kaugelearenenud või metastaatiline rinnanäärmevähk (rinnavähk, mis on hakanud levima organismis ka mujale): Capecitabine Medaci kasutatakse koos dotsetakseeliga (samuti vähiravim) pärast tulemusteta ravi antratsükliinidega (teist liiki vähiravimid).
English: How has Capecitabine Medac been studied?
Estonian: Kuidas Capecitabine Medaci uuriti?
English: What is Capecitabine Medac used for?
Estonian: Milleks Capecitabine Medaci kasutatakse?
English: How is Capecitabine Medac used?
Estonian: Kuidas Capecitabine Medaci kasutatakse?
English: 3 years.
Estonian: 3 aastat.
English: These measures will help to protect the environment.
Estonian: Need meetmed aitavad kaitsta keskkonda.
English: Do not pass it on to others.
Estonian: Ärge andke seda kellelegi teisele.
English: Contains E110.
Estonian: Sisaldab E110.
English: Not applicable.
Estonian: Ei ole kohaldatav.
English: This is to ensure that you receive sufficient treatment.
Estonian: See tagab, et saaksite adekvaatset ravi.
English: - This medicine has been prescribed for you personally.
Estonian: - Ravim on välja kirjutatud isiklikult teile.
English: System organ class
Estonian: Organsüsteemi klass
English: Each bottle contains 250 capsules.
Estonian: Iga pudel sisaldab 250 kapslit.
English: DATE OF REVISION OF THE TEXT
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV
English: OTHER SPECIAL WARNING(S), IF NECESSARY
Estonian: TEISED ERIHOIATUSED (VAJADUSEL)
English: PACKAGE LEAFLET: INFORMATION FOR THE USER
Estonian: PAKENDI INFOLEHT: INFORMATSIOON KASUTAJALE
English: It allows continued monitoring of the benefit/risk balance of the medicinal product.
Estonian: See võimaldab jätkuvalt hinnata ravimi kasu/riski suhet.
English: Ask your pharmacist how to dispose of medicines no longer required.
Estonian: Küsige oma apteekrilt, kuidas hävitatakse ravimeid, mida enam ei vajata.
English: Please consult your doctor if you plan to become pregnant.
Estonian: Palun konsulteerige arstiga, kui soovite rasestuda.
English: Please tell your doctor or your pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Palun informeerige oma arsti või apteekrit, kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid.
English: Taking Wilzin with food and drink
Estonian: Wilzin'i kasutamine koos toidu ja joogiga
English: UNIQUE IDENTIFIER - 2D BARCODE
Estonian: AINULAADNE IDENTIFIKAATOR - 2D-vöötkood
English: UNIQUE IDENTIFIER - HUMAN READABLE DATA
Estonian: AINULAADNE IDENTIFIKAATOR - INIMLOETAVAD ANDMED
English: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Estonian: Piiratud tingimustel väljastatav retseptiravim (vt lisa I: Ravimi omaduste kokkuvõte, lõik 4.2)
English: In order to follow up your condition and treatment your doctor will check your blood and urine on a regular basis.
Estonian: Teie seisundi ja ravi jälgimiseks teeb arst teile regulaarselt vere- ja uriinianalüüse.
English: There are also links to other websites about rare diseases and treatments.
Estonian: Samuti on seal viited teistele kodulehtedele harvaesinevate haiguste ja ravi kohta.
English: No special requirements
Estonian: Erinõuded puuduvad
English: This is usually worst with the first morning dose and disappears after the first days of treatment.
Estonian: See on tavaliselt kõige tugevam esimese hommikuse annusega ja kaob pärast esimesi ravipäevi.
English: However, protein appears to interfere the least.
Estonian: Valk näib siiski kõige vähem häirivat.
English: If you take more Wilzin than you should:
Estonian: Kui te võtate Wilzin'it rohkem, kui ette nähtud:
English: Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Estonian: Sagedus on määratletud järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: This potentially leads to liver damage and neurological disorders.
Estonian: See võib põhjustada maksakahjustusi ja neuroloogilisi häireid.
English: • Children and adolescents:
Estonian: • Lapsed ja noorukid:
English: Data are very limited in children under 6 years but since the disease is fully penetrant, prophylactic treatment should be considered as early as possible.
Estonian: Alla 6 aasta vanustel lastel kasutamise kohta on väga vähe andmeid, ent kuna see haigus on kogu organismi haarav, tuleb ennetavat ravi kaaluda võimalikult varakult.
English: For a full list of excipients, see section 6.1.
Estonian: Täielik abiainete loetelu, vt lõik 6.1.
English: Wilson's disease will persist during the entire lifetime of the patient and therefore the need for this treatment is life-long.
Estonian: Wilsoni tõbi püsib patsiendil kogu elu jooksul, mistõttu seda ravi vajatakse elu lõpuni.
English: Medicines should not be disposed of via wastewater or household waste.
Estonian: Ravimeid ei tohi ära visata kanalisatsiooni kaudu ega koos majapidamisprügiga.
English: • Periodic Safety Update Reports
Estonian: • Perioodilised ohutusaruanded
English: Please discuss with your doctor.
Estonian: Palun arutage seda oma arstiga.
English: Date of first authorisation: 13 October 2004 Date of latest renewal: 13 October 2009
Estonian: Esmase müügiloa väljastamise kuupäev: 13. oktoober 2004 Müügiloa uuendamise kuupäev: 13. oktoober 2009
English: It is very important to continue anti-copper therapy during pregnancy.
Estonian: Väga tähtis on vasevastast ravi raseduse ajal jätkata.
English: What Wilzin contains
Estonian: Mida Wilzin sisaldab
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Estonian: Nõuded asjaomase ravimi perioodiliste ohutusaruannete esitamiseks on sätestatud direktiivi 2001/83/EÜ artikli 107c punkti 7 kohaselt liidu kontrollpäevade loetelus (EURD loetelu) ja iga hilisem uuendus avaldatakse Euroopa ravimite veebiportaalis.
English: Monitoring may detect evidence of insufficient treatment (copper excess) or excessive treatment (copper deficiency), both of which can be harmful, particularly to growing children and pregnant women.
Estonian: Jälgimise tulemusena võib selguda, et ravi on ebapiisav (ülemäärane vasesisaldus) või ülemäärane (vasevaegus), mis võivad mõlemad olla kahjulikud, eriti kasvavatele lastele ja rasedatele.
English: Uncommon: • A decrease in blood red and white cells may occur.
Estonian: Aeg-ajalt: • Võib esineda punaste ja valgete vererakkude vähenemine.
English: Treatment of Wilson's disease.
Estonian: Wilsoni tõve ravi.
English: Pharmacotherapeutic group: various alimentary tract and metabolism products, ATC code: A16AX05.
Estonian: Farmakoterapeutiline grupp: mitmesugused seedeelundkonna ja ainevahetuse tooted, ATC-kood: A16AX05.
English: These side effects may occur with certain frequencies, which are defined as follows: • very common:
Estonian: Kõrvaltoimed esinevad teatud sagedustega ning need on määratletud järgmiselt:
English: What Wilzin looks like and contents of the pack
Estonian: Kuidas Wilzin välja näeb ja pakendi sisu
English: The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Estonian: Müügiloa hoidja peab informeerima Euroopa Komisjoni käesoleva otsusega loa saanud ravimite turustusplaanidest.
English: - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Estonian: - Kui ükskõik milline kõrvaltoimetest muutub tõsiseks või kui te märkate mõnda kõrvaltoimet,
English: • After Wilzin intake, gastric irritation may occur, especially at the beginning of treatment.
Estonian: • Pärast Wilzin'i sissevõtmist võib tekkida maoärritus, eriti ravi algul.
English: Anaemia may be micro-, normo- or macrocytic and is often associated with leukopenia.
Estonian: Aneemia võib olla mikro-, normo- või makrotsüütiline ja seondub sageli leukopeeniaga.
English: POSSIBLE SIDE EFFECTS Like all medicines, Wilzin can cause side effects, although not everybody gets them..
Estonian: Nagu kõik ravimid, võib ka Wilzin põhjustada kõrvaltoimeid, kuid kõigil neid ei teki.
English: frequency cannot be estimated from the available data.
Estonian: • Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel
English: If you become pregnant during therapy with Wilzin, your doctor will decide which treatment and which dose is best in your situation.
Estonian: Kui rasestute Wilzin'iga ravi ajal, otsustab arst, milline ravi ja milline annus sobivad teie seisundiga kõige paremini.
English: Pharmacological and toxicological data available showed large similarities between zinc salts and among animal species.
Estonian: Farmakoloogilised ja toksikoloogilised andmed näitasid tsingisoolade ja loomaliikide vahelisi suuri sarnasusi.
English: Some patients experience stomach upset after the morning dose.
Estonian: Mõnedel patsientidel on pärast hommikust annust seedehäired.
English: • Changes in blood tests have been reported, including an increase in some liver and pancreatic enzymes.
Estonian: • Teatatud on muutustest vereanalüüsides, sealhulgas mõnede maksa ja kõhunäärme ensüümide tasemetes.
English: 4.6 Pregnancy and lactation
Estonian: 4.6 Rasedus ja imetamine
English: In the blood, about 80% of absorbed zinc is distributed to erythrocytes, with most of the remainder being bound to albumin and other plasma proteins.
Estonian: Veres jaguneb ligikaudu 80% imendunud tsingist erütrotsüütidele ja enamik ülejäänud osast seondub albumiini ja teiste plasma valkudega.
English: The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Estonian: Ravimi trükitud pakendi infolehel peab olema vastava ravimipartii kasutamiseks vabastamise eest vastutava tootja nimi ja aadress.
English: 4.5 Interaction with other medicinal products and other forms of interaction
Estonian: 4.5 Koostoimed teiste ravimitega ja muud koostoimed
English: C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Estonian: C. MÜÜGILOA MUUD TINGIMUSED JA NÕUDED
English: Reported adverse reactions are listed below, by system organ class and by frequency.
Estonian: Allpool on loetletud kõrvaltoimed organsüsteemi klasside ja sageduse järgi.
English: 2D barcode carrying the unique identifier included.
Estonian: Lisatud on 2D-vöötkood, mis sisaldab ainulaadset identifikaatorit.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Estonian: Tervishoiutöötajatel palutakse teavitada kõigist võimalikest kõrvaltoimetest riikliku teavitamissüsteemi, mis on loetletud V lisas, kaudu.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV
English: As with other anti-copper agents such as penicillamine, your symptoms may get worse after starting the treatment.
Estonian: Nagu muudegi vasevastaste ainete, näiteks penitsillamiini puhul, võivad teie sümptomid pärast ravi alustamist halveneda.
English: 250 hard capsules.
Estonian: 250 kõvakapslit.
English: 6.5 Nature and contents of container
Estonian: 6.5 Pakendi iseloomustus ja sisu
English: If you have any further questions on the use of this medicine, ask your doctor.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma arstiga.
English: Laboratory follow-up including haematological surveillance and lipoproteins determination should also be performed in order to detect early manifestations of copper deficiency, such as anaemia and/or leukopenia resulting from bone marrow depression, and decrease in HDL cholesterol and HDL/total cholesterol ratio.
Estonian: Samuti on vajalik laboratoorne, sealhulgas hematoloogiline jälgimine ja lipoproteiinide määramine, et avastada vasevaeguse varaseid ilminguid, näiteks aneemiat ja/või leukopeeniat luuüdi depressiooni tagajärjel ning HDL kolesteroolitaseme ja HDL/üldkolesterooli suhte vähenemist.
English: Always take Wilzin exactly as your doctor has told you.
Estonian: Kasutage Wilzin'it alati vastavalt arstilt saadud juhistele.
English: If you forget to take Wilzin: Do not take a double dose to make up for a forgotten individual dose.
Estonian: Kui te unustate Wilzin'it võtta: Ärge võtke kahekordset annust, kui ravim jäi eelmisel korral võtmata.
English: Whether this is related to mobilisation of copper stores or to natural history of the disease remains unclear.
Estonian: Ei ole teada, kas see on seotud vasevarude mobiliseerumisega või haiguse loomuliku kuluga.
English: WHAT WILZIN IS AND WHAT IT IS USED FOR
Estonian: MIS RAVIM ON WILZIN JA MILLEKS SEDA KASUTATAKSE
English: • Adults:
Estonian: • Täiskasvanud:
English: It is extremely important that pregnant Wilson's disease patients continue their therapy during pregnancy.
Estonian: Äärmiselt tähtis on, et Wilsoni tõvega rasedad jätkaksid raseduse ajal ravi.
English: • Risk Management Plan (RMP)
Estonian: • Riskijuhtimiskava Ei kohaldata.
English: Elevations of serum alkaline phosphatase, amylase and lipase may occur after a few weeks of treatment, with levels usually returning to high normal within the first one or two years of treatment.
Estonian: Seerumi leelisfosfataasi-, amülaasi- ja lipaasitasemed võivad tõusta pärast mõnenädalast ravi ja pöörduda ravi esimese aasta või kahe jooksul normaalse vahemiku kõrgemasse ossa tagasi.
English: A change of therapy is recommended in this situation.
Estonian: Sellisel juhul on soovitatav ravi muuta.